Protagenic Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
PTIX Nasdaq 8731 https://protagenic.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Protagenic Therapeutics Inc

Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders - May 22nd, 2024 12:12 pm
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial - May 1st, 2024 12:38 pm
Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit - Apr 17th, 2024 12:42 pm
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - Apr 1st, 2024 8:20 pm
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders - Mar 27th, 2024 12:42 pm
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call - Mar 25th, 2024 9:00 pm
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice - Mar 21st, 2024 12:41 pm
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders - Feb 13th, 2024 1:30 pm
Protagenic Therapeutics Announces Date of Annual Shareholder Meeting - Oct 13th, 2023 1:00 pm